Advanced search
Start date
Betweenand
Related content

Combined inhibition of BET proteins AND HDACs as an effective strategy for the treatment of mammary cancer: a comparative study

Grant number: 19/05778-6
Support type:Scholarships abroad - Research Internship - Doctorate
Effective date (Start): June 18, 2019
Effective date (End): February 17, 2020
Field of knowledge:Agronomical Sciences - Veterinary Medicine - Animal Pathology
Principal researcher:Heidge Fukumasu
Grantee:Pedro Luiz Porfirio Xavier
Supervisor abroad: Susanne Muller-Knapp
Home Institution: Faculdade de Zootecnia e Engenharia de Alimentos (FZEA). Universidade de São Paulo (USP). Pirassununga , SP, Brazil
Research place: Goethe University Frankfurt, Germany  
Associated to the scholarship:17/11966-4 - Epigenetic modulations and self-renewal potential of canine mammary cancer cells: the search for potential therapeutic targets, BP.DR

Abstract

Mammary tumors are the most frequent type of cancer in female dogs as in women. Besides that, its cells share similar features and can be used to comparative studies and screening of antineoplastic agents. Epigenetic targets are highlighted as potential and innovative therapy against cancer. Both histone deacetylases (HDACs) and bromodomain and extraterminal proteins (BET) inhibitors have been shown to be efficient in types of cancer such as lymphoma, leukemia and NUT midline carcinomas. In breast cancer, few studies have observed good effects of these inhibitors. Furthermore, when applying individually, some issues may arise, including incomplete efficacy and drug resistance. Thus, new strategies to overcome these limitations are necessary and one of the possibilities is to test the combined effect of HDAC-BET inhibition using a dual inhibitor. We propose, in this Project, an 8-month internship abroad in Buchmann Institute for Molecular Life Sciences at the Goethe University Frankfurt am Main, Germany to test a new and unpublished dual HDAC-BET inhibitor on breast cancer cells using 2D and 3D in vitro models. We believe that the period will be enough to perform the analysis and the data acquired will determine a possible new strategy for future therapies targeting breast cancer. After that, we will observe the effects of the new dual HDAC-BET inhibitor using canine mammary cancer cells from our laboratory in Brazil finding to a comparative approach which will allow us to elucidate a possible treatment strategy for mammary cancer in both women and dogs.

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
XAVIER, PEDRO LUIZ PORFIRIO; MUELLER, SUSANNE; FUKUMASU, HEIDGE. Epigenetic Mechanisms in Canine Cancer. FRONTIERS IN ONCOLOGY, v. 10, OCT 23 2020. Web of Science Citations: 0.
XAVIER, PEDRO L. P.; CORDEIRO, YONARA G.; ALEXANDRE, PAMELA A.; PIRES, PEDRO R. L.; SARANHOLI, BRUNO H.; SILVA, EDSON R.; MUELLER, SUSANNE; FUKUMASU, HEIDGE. An epigenetic screening determines BET proteins as targets to suppress self-renewal and tumorigenicity in canine mammary cancer cells. SCIENTIFIC REPORTS, v. 9, NOV 22 2019. Web of Science Citations: 0.

Please report errors in scientific publications list by writing to: cdi@fapesp.br.